Randomized trial of three induction antibodies in kidney transplantation: long-term results

Transplantation. 2014 Jun 15;97(11):1128-38. doi: 10.1097/01.TP.0000441089.39840.66.


Background: In searching for an optimal induction regimen, we conducted two separate randomized trials of 38 living donor and 90 deceased donor adult, primary kidney transplant recipients comparing antithymocyte globulin (Thymoglobulin) (group A, N=43) versus alemtuzumab (group B, N=43) versus daclizumab (group C, N=42), using exactly the same three treatment arms in each trial.

Methods: For the purpose of maximizing statistical power, results from the two randomized trials were combined. Groups A and C received standard maintenance dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids. Because of intense lymphodepletion expected with alemtuzumab use (and hoped-for achievement of a truer immunoregulatory state), group B received lower TAC and MMF dosing and corticosteroid avoidance. Long-term target TAC trough level and MMF dosing were 5 to 7 ng/mL and 1,000 mg b.i.d. in groups A and C; 4 to 6 ng/mL and 500 mg b.i.d. in group B.

Results: With median follow-up of 95 months, biopsy-proven cute rejection incidence was similar in the three groups (8/43, 14/43, and 12/42, P=0.34), but biopsy-proven chronic allograft injury incidence was significantly higher in group B (19/43) in comparison with groups A (9/43) and C (7/42) combined (P=0.0008). Mean calculated creatinine clearance was significantly lower in group B versus the average of groups A and C means throughout 60 months posttransplant (62.9±4.2 vs. 83.6±6.9 and 79.8±5.9 at 60 months, P=0.01), and death-censored graft failure was significantly higher in group B (13/43) versus groups A (5/43) and C (5/42) combined (P=0.009). Total infection and new-onset diabetes after transplant rates were not significantly different. Ad hoc analysis suggested that the inferior results in group B were specifically a result of reduced dosing and greater withholding of TAC and MMF occurring in that group.

Conclusions: Long-term results clearly indicate inferior clinical outcomes in group B.

Trial registration: ClinicalTrials.gov NCT00681343 NCT00685061.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / chemistry*
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antilymphocyte Serum / administration & dosage
  • Cadaver
  • Creatinine / blood
  • Daclizumab
  • Female
  • Follow-Up Studies
  • Graft Rejection
  • Graft Survival / immunology
  • Humans
  • Immunoglobulin G / administration & dosage
  • Immunosuppressive Agents / administration & dosage
  • Kidney Transplantation / methods*
  • Living Donors
  • Male
  • Middle Aged
  • Mycophenolic Acid / administration & dosage
  • Mycophenolic Acid / analogs & derivatives
  • Tacrolimus / administration & dosage
  • Treatment Outcome


  • Adrenal Cortex Hormones
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Alemtuzumab
  • Creatinine
  • Daclizumab
  • thymoglobulin
  • Mycophenolic Acid
  • Tacrolimus

Associated data

  • ClinicalTrials.gov/NCT00681343
  • ClinicalTrials.gov/NCT00685061